| Followers | 42 |
| Posts | 4316 |
| Boards Moderated | 0 |
| Alias Born | 07/14/2010 |
Tuesday, September 26, 2023 9:23:53 AM
Book value per share $2.30
Cash Flow Statement
Operating Cash Flow -$169.74M
Levered Free Cash Flow $-71.47M
Profitability
Profit Margin0.00%
Operating Margin 0.00%
Management Effectiveness
Return on Assets -36.10%
Return on Equity -66.41%
Burning $240,000,000,000 B
Cash Flow Statement
Operating Cash Flow -$169.74M
Levered Free Cash Flow $-71.47M
Profitability
Profit Margin0.00%
Operating Margin 0.00%
Management Effectiveness
Return on Assets -36.10%
Return on Equity -66.41%
Burning $240,000,000,000 B
Recent IMVT News
- Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026 • GlobeNewswire Inc. • 05/11/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 10:40:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/01/2026 08:46:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/10/2026 08:05:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/10/2026 08:03:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 08:22:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 08:20:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 08:17:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 08:13:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:33:01 PM
- Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) • GlobeNewswire Inc. • 04/02/2026 09:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:07:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/10/2026 10:16:55 PM
- Immunovant shares climb 7% as fiscal Q3 loss comes in better than expected • IH Market News • 02/06/2026 03:50:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/06/2026 12:24:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2026 12:16:39 PM
- Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 • GlobeNewswire Inc. • 02/06/2026 12:00:00 PM
- Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 • GlobeNewswire Inc. • 01/23/2026 10:25:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2025 09:15:25 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/12/2025 11:01:56 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2025 11:39:33 AM
- Immunovant Announces Pricing of $550 Million Common Stock Financing • GlobeNewswire Inc. • 12/11/2025 06:29:26 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/26/2025 10:07:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/26/2025 12:16:56 AM
